Oxford Biomedica’s long-running alliance with Sanofi over a pair of gene therapies for ophthalmic diseases has come to an end, after an internal review by the French drugmaker.
Sanofi has just spent $16 billion on acquiring Bioverativ and Ablynx – and yesterday’s Q4 results revealed why the firm is in a hurry to diversify its revenues.
Novartis has struck another deal to build its position in radiopharmaceuticals, agreeing to pay $1 billion upfront for radioligand therapy (RLT) developer Mariana Oncology
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.